THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION
https://doi.org/10.21516/2072-0076-2018-11-2-58-61
Abstract
The review presents the analysis and possible ways of solving the issues of treatment of age related macular degeneration (AMD) based on pharmacogenetic approaches. The AMD problem is relevant because of the growing number of resistant neovascular membranes, an increase in the number of older-age patients, and a large number of complications from frequently used anti VEGF therapy as described in the literature. According to literary data, currently the most probable genes whose polymorphisms can affect the metabolism of drugs used, and hence the tactics of AMD treatment are: 1) CFH gene [complement factor H, chromosome 1q32 locus)]; 2) IL-8 gene; 3) ARMS2 gene of increased sensitivity to AMD; 4) VEGF-A gene; 5) NR3C1 gene. The need for diagnostic pharmacogenetic panels to select targeted AMD therapy is discussed. For citation: Bakunina N.А., Shcherbo S.N., Kolesnikova L.N. The prognostic value of pharmacological and genetic testing in medical therapy of age-related macular degeneration. Russian ophthalmological journal. 2018; 11 (2): 58-61. doi: 10.21516/2072-0076-2018-11-2-58-61 (In Russian).
About the Authors
N. A. Bakunina
N.I. Pirogov City Clinical Hospital #1, Moscow, Russia
Russian Federation
Russian Federation
S. N. Shcherbo
N.I. Pirogov Russian State National Research Medical University, Moscow, Russia
Russian Federation
Russian Federation
L. N. Kolesnikova
N.I. Pirogov City Clinical Hospital #1, Moscow, Russia
Russian Federation
Russian Federation
References
1. Бойко Э.В., Чурашов С.В., Камилова Т.А. Молекулярно-генетические основы ВМД. Вестник офтальмологии. 2013; 129(2): 86-90.
2. Будзинская М.В., Погода Т.В., Генерозова Э.В. и др. Современные фармакогенетические подходы к лечению возрастной макулярной дегенерации. Вестник офтальмологии. 2013; 129(5): 127-35.
3. McNamara D. Bevacizumab, Ranibizumab comparable for macular degeneration. Association for Research in Vision and Ophthalmology (ARVO) 2013 Annual Meeting Presented. Washington; May 7, 2013. doi: 10.1056/NEJMoa1102673
4. Martin D.F., Maguire M.G., Fine S.L., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012; 119 (7): 1388-98. doi: 10.1016/j.ophtha.2012.03.053
5. Ersoz M.G, Karacorlu M., Arf S., Sayman Muslubas I., Hocaoglu M. Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management. Surv. Ophthalmol. 2017; 62: 493-505. https://doi.org/10.1016/j.survophthal.2017.03.004
6. Barak Y., Heroman W.J., Tezel T.H. The past, present, and future of exudative age-related macular degeneration treatment. Middle East African Journal of Ophthalmology. 2012; 19(1): 43-51. http://dx.doi.org/10.4103/0974-9233.92115
7. Young M. Chui L., Fallah N., et al. Exacerbation of choroid and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Retina. 2014; Jul;34(7): 1308-15. doi:10.1097/IAE.0000000000000081
8. Schaal S., Kaplan H.J., Tezel T.H. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008; 115 (12): 2199-205. doi: 10.1016/j.ophtha.2008.07.007
9. Hong N., Shen Y., Yu C.Y., Wang, S.Q., Tong J.P. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis. Acta Ophthalmol. 2016; 94: 334-45. doi: 10.1111/aos.13049
10. Broadhead G.K., Hong T., Chang A.A. Treating the untreatable patient current options for the management of treatment-resistent neovascular age-related macular degeneration. Acta Ophthalmol. 2014; 92(8): 713-23. doi: 10.1111/aos.12463
11. Jonas B.J., Libondi T., Golubkina L. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol. 2010; 88(6): 630-4. doi: 10.1111/j.1755-3768.2008.01502
12. Lauer N., Mihlan M., Hartmann A., et al. Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-H His402 risk allele. J. Immun. 2011; 187: 4374-83. doi: https://doi.org/10.4049/jimmunol.1002488
13. Seddon J.M., George S., Rosner B. et al. CFH gene variant Y402H and smoking body mass index environmental associations with advanced age-related macular degeneration. Hum Hered. 2006; 61: 157-65. doi: 10.1159/000094141
14. Yang X., Hu J., Zhang J., Guan H. Polymorphism in CFH HTRA1 and CX3CR1 confer risk to exudative age-related macular degeneration in Han Chinese. Br. J. Ophthalmol. 2010; 94(9): 1211-4. http://dx.doi.org/10.1136/bjo.2009.165811
15. Сhen W. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp. Eye Res. 2009; 89(3):292-300. doi: 10.1016/j.exer.2008.10.017.
16. Hyman L., Nebrosky R. Risk factor for age-related macular degeneration: An update. Curr. Opin. Ophthalmol. 2002; 13(3): 171-5.
17. Finger R.P., Wickremasinghe S.S., Baird P.N., Guymer R.H. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Survey of Ophthalmology. 2014; 59(1): 1-18. doi: 10.1016/j.survophthal.2013.03.009
18. Kepez Yildiz B., Ozdek S., Ergun M.A., et al. CFH Y402H and VEGF polymorphisms and anti-VEGF treatment response in exudative age-related macular degeneration. Ophthalmic Res. 2016; 56(3): 132-8. doi: 10.1159/000446186.
19. Donald T. AMD Risk Alleles predict response to nutritional supplementation. Retina today. 2013; 7 (October): 50-2.
20. Бойко Э.В., Чурашов С.В., Камилова Т.А. Молекулярно-генетические аспекты патогенеза глаукомы. Вестник офтальмологии. 2013; 129(4): 77-82.
21. Будзинская М.В., Погода Т.В., Стрелкова И.Д. Влияние генетических мутаций на клиническую картину субретинальной неоваскуляризации. Вестник офтальмологии. 2011; 127(4): 9-16.
22. Liutkeviciene R. Factors determining age-related macular degeneration: a current view. Medicina (Kaunas) 2010; 46(2): 89-94.
23. Abedi F., Wickremasinghe S., Richardson A.J., et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology. 2013 Jan;120(1): 115-21. doi: 10.1016/j.ophtha.2012.10.006
24. Amoaku W.M., Chkravarthy U., Gale R., et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015; 29(6): 721-31. doi: 10.1038/eye.2015.48
25. Moutray T., Chakravarthy U. Age-related macular degeneration: current treatment and future options. Therapeutic advances in chronic disease. 2011; 2 (5): 325-31. doi: 10.1177/2040622311415895
26. Telander D.G. Inflammation and age-related macular degeneration (AMD). Semin. Ophthalmology. 2011; 26(3): 192-7. doi: 10.3109/08820538.2011.570849
Review
For citations:
Bakunina N.A., Shcherbo S.N., Kolesnikova L.N. THE PROGNOSTIC VALUE OF PHARMACOLOGICAL AND GENETIC TESTING IN MEDICAL THERAPY OF AGE-RELATED MACULAR DEGENERATION. Russian Ophthalmological Journal. 2018;11(2):58-61. (In Russ.) https://doi.org/10.21516/2072-0076-2018-11-2-58-61
Views:
557
Email this article 